[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

ASIA-PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025

October 2017 | 98 pages | ID: AB412233642EN
Inkwood Research

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
KEY FINDINGS

The Asia-Pacific botanical and plant derivative drug market is predicted to rise at 4.10% CAGR over the forecast period of 2017-2025, generating $31578 million by its end. The market is driven by the rising investment of pharmaceutical companies, and increased integration of plant-derived drugs in the market.

MARKET INSIGHTS

The market is segmented on the basis of plant-derived drug type, products, and therapeutic applications. These drugs are less toxic in nature as compared to traditional methods. Indian botanical and plant derivative drug market is expected to exhibit the highest growth over the forecast period. A strong demand for Ayurvedic, Unani and Siddha products have contributed considerably to get a foothold for leading plant-derivative drug manufacturing companies in this region. Also, major steps have been taken towards the adoption of botanical and plant derivative drugs by the governments of other Asia-Pacific countries like Japan, South Korea, China, Australia, etc.

COMPETITIVE INSIGHTS

Abbott Pharmaceuticals, GE Healthcare, GlaxoSmithKline, Glenmark Pharmaceuticals Ltd, Piramal Phytocare Ltd. Bayer Healthcare Llc, Pfizer international, Novartis International Ag, Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd), Lupin Ltd, etc. are some of the well-known companies in the market.
1. RESEARCH SCOPE

1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA
  2.1.1. SECONDARY DATA
  2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY
3.2. KEY FINDINGS
  3.2.1. INDIAN BOTANICAL AND PLANT DERIVATIVE DRUGS MARKET TO OFFER GREAT OPPORTUNITIES
  3.2.2. IN TERMS OF MARKET BY TYPES GLYCOSIDES SEGMENT IS GROWING RAPIDLY
  3.2.3. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
  3.2.4. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY

4. MARKET DYNAMICS

4.1. DRIVERS
  4.1.1. GROWING APPLICATIONS IN DISEASES
  4.1.2. GROWING FDA APPROVALS
  4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
  4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
  4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
  4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
  4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
  4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
  4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
  4.3.3. INCREASING INVESTMENT IN ASIA PACIFIC
4.4. CHALLENGES
  4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
  4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS

5. MARKET SEGMENTATION

5.1. MARKET BY TYPES 2017-2025
  5.1.1. TERPENES
  5.1.2. STEROIDS
  5.1.3. GLYCOSIDES
  5.1.4. PHENOLS
  5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
  5.2.1. ONCOLOGY
  5.2.2. DERMATOLOGY
  5.2.3. CNS DISORDERS
  5.2.4. HORMONE DISEASES
  5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
  5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
  5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
  5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
  5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
  5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
  5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
  5.3.7. HERBAL/TRADITIONAL TONICS

6. KEY ANALYTICS

6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
  6.4.1. THREAT OF NEW ENTRANTS
  6.4.2. THREATS OF SUBSTITUTE PRODUCT
  6.4.3. BARGAINING POWER OF BUYER
  6.4.4. BARGAINING POWER OF SUPPLIER
  6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA

7. GEOGRAPHIC ANALYSIS

7.1. ASIA-PACIFIC
  7.1.1. CHINA
  7.1.2. INDIA
  7.1.3. JAPAN
  7.1.4. AUSTRALIA
  7.1.5. SOUTH KOREA
  7.1.6. REST OF ASIA-PACIFIC

8. COMPETITIVE LANDSCAPE

8.1. KEY STRATEGIES
  8.1.1. MERGER & ACQUISITION
  8.1.2. PARTNERSHIP & COLLABORATION
  8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS

9. COMPANY PROFILE

9.1. ABBOTT LABORATORIES
  9.1.1. OVERVIEW
  9.1.2. PRODUCT PORTFOLIO
  9.1.3. STRATEGIC INITIATIVES
  9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
  9.2.1. OVERVIEW
  9.2.2. PRODUCT PORTFOLIO
  9.2.3. SCOT ANALYSIS
9.3. BIONOVA
  9.3.1. OVERVIEW
  9.3.2. PRODUCT PORTFOLIO
  9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
  9.4.1. OVERVIEW
  9.4.2. STRATEGIC INITIATIVE
  9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
  9.5.1. OVERVIEW
  9.5.2. PRODUCT PORTFOLIO
  9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
  9.6.1. OVERVIEW
  9.6.2. PRODUCT PORTFOLIO
  9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
  9.7.1. OVERVIEW
  9.7.2. PRODUCT PORTFOLIO
  9.7.3. STRATEGIC INITIATIVES
  9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
  9.8.1. OVERVIEW
  9.8.2. PRODUCT PORTFOLIO
  9.8.3. STRATEGIC INITIATIVE
  9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
  9.9.1. OVERVIEW
  9.9.2. PRODUCT PORTFOLIO
  9.9.3. STRATEGIC INITIATIVE
  9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
  9.10.1. OVERVIEW
  9.10.2. PRODUCT PORTFOLIO
  9.10.3. STRATEGIC INITIATIVES
  9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
  9.11.1. OVERVIEW
  9.11.2. PRODUCT PORTFOLIO
  9.11.3. STRATEGIC INITIATIVES
  9.11.4. SCOT ANALYSIS
9.12. PFIZER
  9.12.1. OVERVIEW
  9.12.2. PRODUCT PORTFOLIO
  9.12.3. STRATEGIC INITIATIVE
  9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD.
  9.13.1. OVERVIEW
  9.13.2. PRODUCT PORTFOLIO
  9.13.3. STRATEGIC INITIATIVE
  9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
  9.14.1. OVERVIEW
  9.14.2. PRODUCTION PORTFOLIO
  9.14.3. STRATEGIC INITIATIVE-
  9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
  9.15.1. OVERVIEW
  9.15.2. PRODUCTION PORTFOLIO
  9.15.3. SCOT ANALYSIS

LIST OF TABLES

Table 1 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
Table 2 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
Table 3 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
Table 4 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Table 5 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
Table 6 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
Table 7 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Table 8 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 9 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
Table 10 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
Table 11 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
Table 12 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 13 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
Table 14 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
Table 15 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
Table 16 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
Table 17 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
Table 18 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 19 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 20 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
Table 21 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)

LIST OF FIGURES

Figure 1 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 2 INDIA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 3 ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 4 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
Figure 5 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Figure 6 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 7 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
Figure 8 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Figure 9 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
Figure 10 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
Figure 11 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
Figure 12 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
Figure 13 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
Figure 14 ASIA PACIFIC BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Figure 15 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
Figure 16 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
Figure 17 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
Figure 18 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
Figure 19 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 20 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 21 ASIA PACIFIC BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
Figure 22 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
Figure 23 CHINA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 24 INDIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 25 JAPAN BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 26 AUSTRALIA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 27 SOUTH KOREA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 28 REST OF ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)


More Publications